• CSS Log In
  • Language
  • Transcriptome Sequencing
  • Eukaryote
  • mRNA Sequencing
  • Non-coding RNA Sequencing
  • Long Non-coding RNA Sequencing
  • Small RNA Sequencing
  • Circular RNA Sequencing
  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics
  • Whole Genome Bisulfite Sequencing (Gene Methylation)
  • Reduced Representation Bisulfite Sequencing (RRBS-Gene Methylation)
  • ChIP-Seq
  • RIP-Seq
  • Metagenomics
  • 16S/18S/ITS Amplicon Metagenomic Sequencing
  • Shotgun Metagenomic Sequencing
  • Pre-made Library Sequencing
  • Pre-made Library Sequencing
  • Clinical Diagnostics
  • Clinical Whole Exome Sequencing (CLIA/CAP)
  • Clinical Panels
  • Genetic Testing
  • Oncology
  • NovoPM™ 2.0
  • NovoFocus™ NSCLC 2.0
  • NovoFocus™ CRC 2.0
  • NovoFocus™ PARPi CDx 1.0
  • NovoFocus™ CR
  • Cancer Immunotherapy Biomarkers
  • Patient's Case Study
  • Service Support
  • Service Workflow
  • Sample Preparation Guide
  • Sample Requirements
  • Quality Management
  • Data Analysis
  • FAQs​​
  • Technology
  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Resources
  • Publications
  • Downloads
  • Brochure/Magazine
  • Webinars
  • About
  • About Us
  • Major Milestones
  • News & Events
  • Careers
  • Partnership
  • Contact Us
  • De novo Sequencing
  • Animal & Plant De novo Sequencing
  • Microbial De novo Sequencing
  • Transcriptome Sequencing

  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics

    Metagenomics

    Pre-made Library Sequencing

  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Publications
  • Downloads
  • Brochure/Magazine
  • Webinars
  • About Us
  • Major Milestones
  • News & Events
  • Careers
  • Partnership
  • お問い合わせは こちら
    皆様の研究の ニーズに関して お気軽にご相談ください
    Clinical Panels

    NovoPM™ 2.0

    Comprehensive genomic profiling for 484 cancer-related genes to help you give the right treatment for your patients

    The Novogene Precision Medicine 2.0 (NovoPM™ 2.0) comprehensive genomic profiling test for solid tumors is a next generation sequencing (NGS)-based assay that analyzes 484 genes for clinically important alterations at the DNA level. These genes are known to be relevant for the diagnosis and/or treatment of various solid tumors according to National Comprehensive Cancer Network (NCCN) Guidelines and the medical literature. All tests are performed in our CAP-accredited lab and analyzed by our in-house bioinformatics specialists. Report generated provides tailored treatment recommendations for your patients.

    NovoPM™ 2.0 is developed based on NovoPM™ 1.0 with updated gene list and enhanced analytical performance.

    Parameters

    NovoPM™ 2.0
    Cancer type
    All Solid Tumors
    Sample type
    Extracted DNA
    FFPE
    Whole blood
    Blood Pasma
    Extracted cfDNA
    Turnaround time
    ≤ 2 weeks
    Novogene Quality Assurance
    Comprehensive Results

    NovoPMTM 2.0 interrogates the complete coding regions of 468 genes and the introns of 43 genes. It can detect all four types of genomic abnormalities(SNV, InDel, CNV and Fusion) and also generate results (TMB, bTMB and MSI)that can help guide cancer immunotherapies.

    Reliable Performance

    Comprehensive analytical validation has been completed ant the test includes rigorous quality control measures.

    Ultra-fast Sample Importation (when necessary)

    As a high-tech life science company in Beijing, Novogene can utilize a government-authorized "green channel" for ultra-fast importation of clinical samples through the Beijing Customs, When necessary.

    Competitive Price

    With one of the world's largest sequencing capacity and superior process efficiency, Novogene offers highly competitive prices for all services.

    Who Benefits from NovoPM™ 2.0 ?
  • Individuals with advanced or late stage cancers.
  • Individuals who have tested negative for single gene mutations and require a more comprehensive tumor profiling.
  • Individuals with cancers of unknown primary origin.
  • Individuals with inadequate amount of tissue or unobtainable tissue for biopsy.
  • Individuals who may prefer non-invasive testing or are not suitable for invasive surgical procedure.
  • Gene Targets

    NovoPM™ 2.0 interrogates the complete coding regions of 468 genes and the introns of 43 genes for all four types of genomic abnormalities: SNV, InDel, CNV and fusion. A comparison of the gene lists between NovoPM™ 2.0 and the FDA-approved FoundationOne CDx is shown in Figure 3. The mutation status of some of these genes can guide the potential application of multiple FDA-approved targeted and/or immunotherapies as shown in Table 1. The other genes are also analyzed for their relevance to the diagnosis and/or treatment of various solid tumors according to the medical literature. The clinical interpretation of detected mutations in those genes is done according to Novogene’s comprehensive in-house oncology knowledgebase constructed based on public resources including GeneCards, CKB, OncoKB, COSMIC, ClinVar PMC, Drugs@FDA, Drug Information Portal (NIH), Selleck, PharmGKB, DGIdb, DRUGBANK, Drugs.com, ClinicalTrials.gov, ICTRP, ChiCTR, KEGG and Cell Signaling. In addition, our oncology knowledgebase incorporates ~1,000 germline BRCA1/2 variants previously reported to be unique in Chinese breast cancer and ovarian cancer patients1.

    Figure 1. NovoPMTM 2.0 vs. FoundationOne CDx

    Table 1. Gene targets in NovoPMTM 2.0 that are associated with FDA-approved or NCCN-recommended therapies

    Indication
    Biomarkers
    FDA-approved or NCCN-recommended therapies
    Non-Small Cell Lung Cancer
    EGFR 19Del and L858R
    Gilotrif® (afatinib), Iressa® (gefitinib) or Tarceva® (erlotinib)
    EGFR T90M
    Tegrisso® (osimertinib)
    ALK rearrangements
    Alecensa® (alectinib), Xalkori® (crizotinib), Zykadia® (ceritinib), Alunbrig® (brigatinib) or Lorbrena® (Lorlatinib)
    BRAF V600E
    Tafinlar® (dabrafenib) + Mekinist® (trametinib)
    ROS1 fusion
    Xalkori® (crizotinib) or Rozlytrek® (entrectinib)
    TMB and bTMB
    Opdivo® (nivolumab), Keytruda® (pembrolizumab), or Tecentriq® (atezolizumab)
    Melanoma
    BRAF V600E or V600k
    Tafinlar® (dabrafenib), Tafinlar® (dabrafenib) + Mekinist® (trametinib), Zelboraf® (vemurafenib) or Braftovi® (encorafenib) + Mektovi® (binimetinib)
    Breast Cancer
    ERBB2 (HER2) amplification
    Herceptin® (trastuzumab), Perjeta® (pertuzumab), Tykerb® (lapatinib) or Nerlynx (neratinib)
    gBRCA alterations and ERBB2 (HER2) negative
    Talzenna® (talazoparib) or Lynparza® (olaparib)
    PIK3CA alterations
    Piqray® (Alpelisib)
    Colorectal Cancer
    RAS wild-type
    Erbitux® (cetuximab), Vectibix® (panitumumab) or Stivarga® (regorafenib)
    MSI-H
    Keytruda® (pembrolizumab), Opdivo® (nivolumab) or Opdivo® (nivolumab) + Yervoy® (ipilimumab)
    Ovarian Cancer
    BRCA1 and BRCA2 alterations
    Lynparza® (olaparib) or Rubraca® (rucaparib)
    Solid Tumors
    MIS-H
    Keytruda® (pembrolizumab)
    NTRK1/2/3 fusions
    Vitrakvi® (larotrectinib) or Rozlytrek® (entrectinib)

    Sample Requirements

    Sample Type
    Sample Requirement
    FFPE
    Approximately ten 4-µm sections, each with tissue area ≥ 25 mm2 and tumor content ≥ 20%.
    Whole blood
    10 mL (for ctDNA and white blood cell DNA extraction)
    Blood Plasma
    4 mL (for ctDNA extraction)

    Testing Workflow